Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 20 July 1979:
Vol. 205. no. 4403, pp. 298 - 299
DOI: 10.1126/science.451601
Prev | Table of Contents | Next

Articles

Science, Vol 205, Issue 4403, 298-299
Copyright © 1979 by American Association for the Advancement of Science

articles

Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity

A Nicholson and IH Lepow

Some individuals, with severe or recurrent infection with Neisseria species, have been identified as lacking a component in the terminal attack sequence of complement (complement components 5 to 9). The relevance of the terminal attack sequence to various phases of host defense was tested with the use of the C-11 strain of meningococci and human serum genetically deficient in complement component 8 (C8-D). The C8-D serum was comparable to normal serum in supporting ingestion and intracellular killing by leukocytes but was not bactericidal in the fluid phase unless reconstituted with C8. Thus, serum complement-dependent bactericidal activity may be especially critical for the host's defense against invasive Neisseria species.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera.
D. M. Granoff, J. A. Welsch, and S. Ram (2009)
Infect. Immun. 77, 764-769
   Abstract »    Full Text »    PDF »
Important Role for Toll-Like Receptor 9 in Host Defense against Meningococcal Sepsis.
H. Sjolinder, T. H. Mogensen, M. Kilian, A.-B. Jonsson, and S. R. Paludan (2008)
Infect. Immun. 76, 5421-5428
   Abstract »    Full Text »    PDF »
A Glycoconjugate Vaccine for Neisseria meningitidis Induces Antibodies in Human Infants That Afford Protection against Meningococcal Bacteremia in a Neonate Rat Challenge Model.
K. T. Mountzouros, K. A. Belanger, A. P. Howell, G. S. Bixler Jr., and D. V. Madore (2002)
Infect. Immun. 70, 6576-6582
   Abstract »    Full Text »    PDF »
Production of Neisseria meningitidis Transferrin-Binding Protein B by Recombinant Bordetella pertussis.
I. Coppens, S. Alonso, R. Antoine, F. Jacob-Dubuisson, G. Renauld-Mongenie, E. Jacobs, and C. Locht (2001)
Infect. Immun. 69, 5440-5446
   Abstract »    Full Text »    PDF »
Humoral Immune Responses to Neisseria meningitidis in Children.
A. J. Pollard, R. Galassini, E. M. Rouppe van der Voort, R. Booy, P. Langford, S. Nadel, C. Ison, J. S. Kroll, J. Poolman, and M. Levin (1999)
Infect. Immun. 67, 2441-2451
   Abstract »    Full Text »    PDF »
The (alpha 2right-arrow8)-Linked Polysialic Acid Capsule and Lipooligosaccharide Structure Both Contribute to the Ability of Serogroup B Neisseria meningitidis To Resist the Bactericidal Activity of Normal Human Serum.
C. M. Kahler, L. E. Martin, G. C. Shih, M. M. Rahman, R. W. Carlson, and D. S. Stephens (1998)
Infect. Immun. 66, 5939-5947
   Abstract »    Full Text »    PDF »
Age-Dependent Neisseria meningitidis Serogroup C Class-Specific Antibody Concentrations and Bactericidal Titers in Sera from Young Children from Montana Immunized with a Licensed Polysaccharide Vaccine.
S. E. Maslanka, J. W. Tappero, B. D. Plikaytis, R. S. Brumberg, J. K. Dykes, L. L. Gheesling, K. B. J. Donaldson, A. Schuchat, J. Pullman, M. Jones, et al. (1998)
Infect. Immun. 66, 2453-2459
   Abstract »    Full Text »    PDF »
Meningococcemia and Acquired Complement Deficiency: Association in Patients With Hepatic Failure.
R. T. Ellison III, S. R. Mason, P. F. Kohler, J. G. Curd, and L. B. Reller (1986)
Arch Intern Med 146, 1539-1540
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)